CoChat
Sign Up
Cited by 27Cancer Cells and Metastasis3D Printing in Biomedical ResearchMathematical Biology Tumor Growth

The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery

Open access
Bae, JuneSung, Choi, Yun Sik, Cho, Gunsik, Jang, Se Jin·2022·Cancers
DOI 10.3390/cancers14092144PMC PMC9105149
Open this paper in CoChat — free accountOpen PDF

Abstract

The cancer burden is rapidly increasing in most countries, and thus, new anticancer drugs for effective cancer therapy must be developed. Cancer model systems that recapitulate the biological processes of human cancers are one of the cores of the drug development process. PDCO has emerged as a unique model that preserves the genetic, physiological, and histologic characteristics of original cancer, including inter- and intratumoral heterogeneities. Due to these advantages, the PCDO model is increasingly investigated for anticancer drug screening and efficacy testing, preclinical patient stratification, and precision medicine for selecting the most effective anticancer therapy for patients. Here, we review the prospects and limitations of PDCO compared to the conventional cancer models. With advances in culture success rates, co-culture systems with the tumor microenvironment, organoid-on-a-chip technology, and automation technology, PDCO will become the most promising model to develop anticancer drugs and precision medicine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14092144

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Incorporation of patient-derived iPSCs into this system could further enhance its utility for personalized medicine, enabling the prediction of individual drug responses or disease progression.

    “The incorporation of patient-derived iPSCs into this system could further enhance its utility for personalized medicine, enabling the prediction of individual drug responses or disease progression42.”

    From ​Temporal proteomic profiling of iPSC-derived human liver organoids reveals optimal maturation for drug metabolism and toxicology (2026) · cites this paper as [42]

    Section 3.3, “Precision Cancer Medicine” (page unavailable), says patient-derived cancer organoids can predict a patient’s drug response and help predict clinical outcomes. Section 3 mentions induced pluripotent stem cells as one source of organoids, but the paper does not say that incorporating patient-derived iPSCs into the proposed system would enhance it or enable prediction of disease progression. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 206

  1. [1]Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338 · DOI · Paper page
  2. [2]Turner M.C. Andersen Z.J. Baccarelli A. Diver W.R. Gapstur S.M. Pope C.A. 3rd Prada D. Samet J. Thurston G. Cohen A. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations CA Cancer J. Clin. 2020 70 460 479 10.3322/caac.21632 32964460 PMC7904962 · DOI
  3. [3]Vieira V.M. VoPham T. Bertrand K.A. James P. DuPre N. Tamimi R.M. Laden F. Hart J.E. Contribution of socioeconomic and environmental factors to geographic disparities in breast cancer risk in the Nurses’ Health Study II Environ. Epidemiol. 2020 4 e080 10.1097/EE9.0000000000000080 33344878 PMC7747944 · DOI
  4. [4]Boffetta P. Nyberg F. Contribution of environmental factors to cancer risk Br. Med. Bull. 2003 68 71 94 10.1093/bmp/ldg023 14757710 · DOI
  5. [5]Emmons K.M. Colditz G.A. Realizing the Potential of Cancer Prevention—The Role of Implementation Science N. Engl. J. Med. 2017 376 986 990 10.1056/NEJMsb1609101 28273020 PMC5473684 · DOI
  6. [6]Colditz G.A. Wolin K.Y. Gehlert S. Applying what we know to accelerate cancer prevention Sci. Transl. Med. 2012 4 127rv124 10.1126/scitranslmed.3003218 PMC3343638 22461645 · DOI
  7. [7]Advancing Cancer Therapy Nat. Cancer 2021 2 245 246 10.1038/s43018-021-00192-x 35121963 · DOI
  8. [8]Paul S.M. Mytelka D.S. Dunwiddie C.T. Persinger C.C. Munos B.H. Lindborg S.R. Schacht A.L. How to improve R&D productivity: The pharmaceutical industry’s grand challenge Nat. Rev. Drug Discov. 2010 9 203 214 10.1038/nrd3078 20168317 · DOI · Paper page
  9. [9]Scannell J.W. Blanckley A. Boldon H. Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discov. 2012 11 191 200 10.1038/nrd3681 22378269 · DOI · Paper page
  10. [10]Wong C.H. Siah K.W. Lo A.W. Estimation of clinical trial success rates and related parameters Biostatistics 2019 20 273 286 10.1093/biostatistics/kxx069 29394327 PMC6409418 · DOI · Paper page
  11. [11]Corro C. Novellasdemunt L. Li V.S.W. A brief history of organoids Am. J. Physiol. Cell Physiol. 2020 319 C151 C165 10.1152/ajpcell.00120.2020 32459504 PMC7468890 · DOI · Paper page
  12. [12]Barretina J. Caponigro G. Stransky N. Venkatesan K. Margolin A.A. Kim S. Wilson C.J. Lehar J. Kryukov G.V. Sonkin D. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 2012 483 603 607 10.1038/nature11003 22460905 PMC3320027 · DOI · Paper page
  13. [13]Lee J.K. Liu Z. Sa J.K. Shin S. Wang J. Bordyuh M. Cho H.J. Elliott O. Chu T. Choi S.W. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy Nat. Genet. 2018 50 1399 1411 10.1038/s41588-018-0209-6 30262818 PMC8514738 · DOI
  14. [14]Invrea F. Rovito R. Torchiaro E. Petti C. Isella C. Medico E. Patient-derived xenografts (PDXs) as model systems for human cancer Curr. Opin. Biotechnol. 2020 63 151 156 10.1016/j.copbio.2020.01.003 32070860 · DOI
  15. [15]Lancaster M.A. Knoblich J.A. Organogenesis in a dish: Modeling development and disease using organoid technologies Science 2014 345 1247125 10.1126/science.1247125 25035496 · DOI · Paper page
  16. [16]Dietlein F. Weghorn D. Taylor-Weiner A. Richters A. Reardon B. Liu D. Lander E.S. Van Allen E.M. Sunyaev S.R. Identification of cancer driver genes based on nucleotide context Nat. Genet. 2020 52 208 218 10.1038/s41588-019-0572-y 32015527 PMC7031046 · DOI
  17. [18]Margulies E.H. Blanchette M. Program N.C.S. Haussler D. Green E.D. Identification and characterization of multi-species conserved sequences Genome Res. 2003 13 2507 2518 10.1101/gr.1602203 14656959 PMC403793 · DOI
  18. [19]Margoliash E. Primary Structure and Evolution of Cytochrome C Proc. Natl. Acad. Sci. USA 1963 50 672 679 10.1073/pnas.50.4.672 14077496 PMC221244 · DOI
  19. [20]Ben-David U. Siranosian B. Ha G. Tang H. Oren Y. Hinohara K. Strathdee C.A. Dempster J. Lyons N.J. Burns R. Genetic and transcriptional evolution alters cancer cell line drug response Nature 2018 560 325 330 10.1038/s41586-018-0409-3 30089904 PMC6522222 · DOI · Paper page
  20. [22]Wilding J.L. Bodmer W.F. Cancer cell lines for drug discovery and development Cancer Res. 2014 74 2377 2384 10.1158/0008-5472.CAN-13-2971 24717177 · DOI · Paper page
  21. [23]Gazdar A.F. Gao B. Minna J.D. Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer 2010 68 309 318 10.1016/j.lungcan.2009.12.005 20079948 PMC3110769 · DOI
  22. [24]Gazdar A.F. Girard L. Lockwood W.W. Lam W.L. Minna J.D. Lung cancer cell lines as tools for biomedical discovery and research J. Natl. Cancer Inst. 2010 102 1310 1321 10.1093/jnci/djq279 20679594 PMC2935474 · DOI
  23. [25]Borst P. Wessels L. Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 2010 9 4836 4840 10.4161/cc.9.24.14326 21150277 · DOI
  24. [26]Borrell B. How accurate are cancer cell lines? Nature 2010 463 858 10.1038/463858a 20164888 · DOI
  25. [27]Neve R.M. Chin K. Fridlyand J. Yeh J. Baehner F.L. Fevr T. Clark L. Bayani N. Coppe J.P. Tong F. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 2006 10 515 527 10.1016/j.ccr.2006.10.008 17157791 PMC2730521 · DOI
  26. [28]Sharma S.V. Haber D.A. Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat. Rev. Cancer 2010 10 241 253 10.1038/nrc2820 20300105 · DOI
  27. [29]Sporn M.B. Liby K.T. Cancer chemoprevention: Scientific promise, clinical uncertainty Nat. Clin. Pract. Oncol. 2005 2 518 525 10.1038/ncponc0319 16205771 · DOI
  28. [30]Ben-David U. Ha G. Tseng Y.Y. Greenwald N.F. Oh C. Shih J. McFarland J.M. Wong B. Boehm J.S. Beroukhim R. Patient-derived xenografts undergo mouse-specific tumor evolution Nat. Genet. 2017 49 1567 1575 10.1038/ng.3967 28991255 PMC5659952 · DOI · Paper page
  29. [31]Hidalgo M. Amant F. Biankin A.V. Budinska E. Byrne A.T. Caldas C. Clarke R.B. de Jong S. Jonkers J. Maelandsmo G.M. Patient-derived xenograft models: An emerging platform for translational cancer research Cancer Discov. 2014 4 998 1013 10.1158/2159-8290.CD-14-0001 25185190 PMC4167608 · DOI
  30. [32]Dangles-Marie V. Pocard M. Richon S. Weiswald L.B. Assayag F. Saulnier P. Judde J.G. Janneau J.L. Auger N. Validire P. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features Cancer Res. 2007 67 398 407 10.1158/0008-5472.CAN-06-0594 17210723 · DOI
  31. [33]Bergamaschi A. Hjortland G.O. Triulzi T. Sorlie T. Johnsen H. Ree A.H. Russnes H.G. Tronnes S. Maelandsmo G.M. Fodstad O. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models Mol. Oncol. 2009 3 469 482 10.1016/j.molonc.2009.07.003 19713161 PMC5527532 · DOI
  32. [34]Zhao X. Liu Z. Yu L. Zhang Y. Baxter P. Voicu H. Gurusiddappa S. Luan J. Su J.M. Leung H.C. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma Neuro Oncol. 2012 14 574 583 10.1093/neuonc/nos061 22459127 PMC3337308 · DOI
  33. [35]Jung J. Seol H.S. Chang S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research Cancer Res. Treat. 2018 50 1 10 10.4143/crt.2017.307 28903551 PMC5784646 · DOI
  34. [36]Takebe T. Zhang R.R. Koike H. Kimura M. Yoshizawa E. Enomura M. Koike N. Sekine K. Taniguchi H. Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant Nat. Protoc. 2014 9 396 409 10.1038/nprot.2014.020 24457331 · DOI
  35. [40]Lancaster M.A. Renner M. Martin C.A. Wenzel D. Bicknell L.S. Hurles M.E. Homfray T. Penninger J.M. Jackson A.P. Knoblich J.A. Cerebral organoids model human brain development and microcephaly Nature 2013 501 373 379 10.1038/nature12517 23995685 PMC3817409 · DOI · Paper page
  36. [42]Sato T. Vries R.G. Snippert H.J. van de Wetering M. Barker N. Stange D.E. van Es J.H. Abo A. Kujala P. Peters P.J. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche Nature 2009 459 262 265 10.1038/nature07935 19329995 · DOI · Paper page
  37. [44]Kim M. Mun H. Sung C.O. Cho E.J. Jeon H.J. Chun S.M. Jung D.J. Shin T.H. Jeong G.S. Kim D.K. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening Nat. Commun. 2019 10 3991 10.1038/s41467-019-11867-6 31488816 PMC6728380 · DOI · Paper page
  38. [46]Boretto M. Maenhoudt N. Luo X. Hennes A. Boeckx B. Bui B. Heremans R. Perneel L. Kobayashi H. Van Zundert I. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening Nat. Cell Biol. 2019 21 1041 1051 10.1038/s41556-019-0360-z 31371824 · DOI
  39. [47]Li X. Francies H.E. Secrier M. Perner J. Miremadi A. Galeano-Dalmau N. Barendt W.J. Letchford L. Leyden G.M. Goffin E.K. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics Nat. Commun. 2018 9 2983 10.1038/s41467-018-05190-9 30061675 PMC6065407 · DOI · Paper page
  40. [48]Seidlitz T. Merker S.R. Rothe A. Zakrzewski F. von Neubeck C. Grutzmann K. Sommer U. Schweitzer C. Scholch S. Uhlemann H. Human gastric cancer modelling using organoids Gut 2019 68 207 217 10.1136/gutjnl-2017-314549 29703791 PMC6352409 · DOI
  41. [52]Boj S.F. Hwang C.-I. Baker L.A. Chio I.I.C. Engle D.D. Corbo V. Jager M. Ponz-Sarvise M. Tiriac H. Spector M.S. Organoid models of human and mouse ductal pancreatic cancer Cell 2015 160 324 338 10.1016/j.cell.2014.12.021 25557080 PMC4334572 · DOI · Paper page
  42. [54]Jacob F. Salinas R.D. Zhang D.Y. Nguyen P.T.T. Schnoll J.G. Wong S.Z.H. Thokala R. Sheikh S. Saxena D. Prokop S. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity Cell 2020 180 188 204.e22 10.1016/j.cell.2019.11.036 31883794 PMC7556703 · DOI · Paper page
  43. [55]Cho E.J. Kim M. Jo D. Kim J. Oh J.H. Chung H.C. Lee S.H. Kim D. Chun S.M. Kim J. Immuno-genomic classification of colorectal cancer organoids reveals cancer cells with intrinsic immunogenic properties associated with patient survival J. Exp. Clin. Cancer Res. 2021 40 230 10.1186/s13046-021-02034-1 34256801 PMC8276416 · DOI
  44. [56]Liu L. Yu L. Li Z. Li W. Huang W. Patient-derived organoid (PDO) platforms to facilitate clinical decision making J. Transl. Med. 2021 19 40 10.1186/s12967-020-02677-2 33478472 PMC7821720 · DOI
  45. [57]Gomez G.A. Oksdath M. Brown M.P. Ebert L.M. New approaches to model glioblastoma in vitro using brain organoids: Implications for precision oncology Transl. Cancer Res. 2019 8 S606 S611 10.21037/tcr.2019.09.08 35117142 PMC8798484 · DOI
  46. [59]LeSavage B.L. Suhar R.A. Broguiere N. Lutolf M.P. Heilshorn S.C. Next-generation cancer organoids Nat. Mater. 2022 21 143 159 10.1038/s41563-021-01057-5 34385685 PMC12276900 · DOI
  47. [60]Pauli C. Hopkins B.D. Prandi D. Shaw R. Fedrizzi T. Sboner A. Sailer V. Augello M. Puca L. Rosati R. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine Cancer Discov. 2017 7 462 477 10.1158/2159-8290.CD-16-1154 28331002 PMC5413423 · DOI
  48. [61]Clohessy J.G. Pandolfi P.P. Mouse hospital and co-clinical trial project--from bench to bedside Nat. Rev. Clin. Oncol. 2015 12 491 498 10.1038/nrclinonc.2015.62 25895610 · DOI
  49. [62]Voest E.E. Bernards R. DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance? Cancer Discov. 2016 6 130 132 10.1158/2159-8290.CD-15-1321 26851184 · DOI
  50. [63]Zehir A. Benayed R. Shah R.H. Syed A. Middha S. Kim H.R. Srinivasan P. Gao J. Chakravarty D. Devlin S.M. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Nat. Med. 2017 23 703 713 10.1038/nm.4333 28481359 PMC5461196 · DOI · Paper page
  51. [64]Kopper O. de Witte C.J. Lohmussaar K. Valle-Inclan J.E. Hami N. Kester L. Balgobind A.V. Korving J. Proost N. Begthel H. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity Nat. Med. 2019 25 838 849 10.1038/s41591-019-0422-6 31011202 · DOI · Paper page
  52. [66]Francies H.E. Barthorpe A. McLaren-Douglas A. Barendt W.J. Garnett M.J. Drug Sensitivity Assays of Human Cancer Organoid Cultures Methods Mol. Biol. 2019 1576 339 351 10.1007/7651_2016_10 27628132 PMC6527507 · DOI
  53. [68]Yan H.H.N. Siu H.C. Law S. Ho S.L. Yue S.S.K. Tsui W.Y. Chan D. Chan A.S. Ma S. Lam K.O. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening Cell Stem Cell 2018 23 882 897.e11 10.1016/j.stem.2018.09.016 30344100 · DOI · Paper page
  54. [69]Lee S. Chang J. Kang S.M. Parigoris E. Lee J.H. Huh Y.S. Takayama S. High-throughput formation and image-based analysis of basal-in mammary organoids in 384-well plates Sci. Rep. 2022 12 317 10.1038/s41598-021-03739-1 35013350 PMC8748891 · DOI
  55. [71]Czerniecki S.M. Cruz N.M. Harder J.L. Menon R. Annis J. Otto E.A. Gulieva R.E. Islas L.V. Kim Y.K. Tran L.M. High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping Cell Stem Cell 2018 22 929 940.e4 10.1016/j.stem.2018.04.022 29779890 PMC5984728 · DOI · Paper page
  56. [72]Driehuis E. Kretzschmar K. Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications Nat. Protoc. 2020 15 3380 3409 10.1038/s41596-020-0379-4 32929210 · DOI
  57. [73]Golebiewska A. Hau A.C. Oudin A. Stieber D. Yabo Y.A. Baus V. Barthelemy V. Klein E. Bougnaud S. Keunen O. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology Acta Neuropathol. 2020 140 919 949 10.1007/s00401-020-02226-7 33009951 PMC7666297 · DOI
  58. [74]Driehuis E. van Hoeck A. Moore K. Kolders S. Francies H.E. Gulersonmez M.C. Stigter E.C.A. Burgering B. Geurts V. Gracanin A. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening Proc. Natl. Acad. Sci. USA 2019 116 26580 26590 10.1073/pnas.1911273116 31818951 PMC6936689 · DOI
  59. [75]Kodack D.P. Farago A.F. Dastur A. Held M.A. Dardaei L. Friboulet L. von Flotow F. Damon L.J. Lee D. Parks M. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care Cell Rep. 2017 21 3298 3309 10.1016/j.celrep.2017.11.051 29241554 PMC5745232 · DOI
  60. [76]Wang H. Lu J. Tang J. Chen S. He K. Jiang X. Jiang W. Teng L. Establishment of patient-derived gastric cancer xenografts: A useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways BMC Cancer 2017 17 191 10.1186/s12885-017-3177-9 28292264 PMC5348902 · DOI
  61. [77]Cybulska M. Olesinski T. Goryca K. Paczkowska K. Statkiewicz M. Kopczynski M. Grochowska A. Unrug-Bielawska K. Tyl-Bielicka A. Gajewska M. Challenges in Stratifying the Molecular Variability of Patient-Derived Colon Tumor Xenografts BioMed Res. Int. 2018 2018 2954208 10.1155/2018/2954208 30662905 PMC6313970 · DOI
  62. [78]Mukohyama J. Shimono Y. Yamashita K. Sumi Y. Mukohara T. Minami H. Kakeji Y. Effect of Xenotransplantation Site on MicroRNA Expression of Human Colon Cancer Stem Cells Anticancer Res. 2016 36 3679 3686 27354640
  63. [79]Chen Y. Zhang R. Wang L. Correa A.M. Pataer A. Xu Y. Zhang X. Ren C. Wu S. Meng Q.H. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice Cancer 2019 125 3738 3748 10.1002/cncr.32366 31287557 PMC7294643 · DOI
  64. [80]Jung J. Lee C.H. Seol H.S. Choi Y.S. Kim E. Lee E.J. Rhee J.K. Singh S.R. Jun E.S. Han B. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature Oncotarget 2016 7 62533 62546 10.18632/oncotarget.11530 27613834 PMC5308744 · DOI
  65. [81]Hernandez M.C. Bergquist J.R. Leiting J.L. Ivanics T. Yang L. Smoot R.L. Nagorney D.M. Truty M.J. Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens J. Gastrointest. Surg. 2019 23 818 824 10.1007/s11605-019-04109-z 30756315 · DOI
  66. [82]Rosfjord E. Lucas J. Li G. Gerber H.P. Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology Biochem. Pharmacol. 2014 91 135 143 10.1016/j.bcp.2014.06.008 24950467 · DOI
  67. [83]Risbridger G.P. Toivanen R. Taylor R.A. Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models Cold Spring Harb. Perspect. Med. 2018 8 a030536 10.1101/cshperspect.a030536 29311126 PMC6071547 · DOI
  68. [84]Kim M.P. Evans D.B. Wang H. Abbruzzese J.L. Fleming J.B. Gallick G.E. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice Nat. Protoc. 2009 4 1670 1680 10.1038/nprot.2009.171 19876027 PMC4203372 · DOI
  69. [85]Oshi M. Okano M. Maiti A. Rashid O.M. Saito K. Kono K. Matsuyama R. Endo I. Takabe K. Novel Breast Cancer Brain Metastasis Patient-Derived Orthotopic Xenograft Model for Preclinical Studies Cancers 2020 12 444 10.3390/cancers12020444 PMC7072242 32074948 · DOI
  70. [86]Puig I. Chicote I. Tenbaum S.P. Arques O. Herance J.R. Gispert J.D. Jimenez J. Landolfi S. Caci K. Allende H. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells Clin. Cancer Res. 2013 19 6787 6801 10.1158/1078-0432.CCR-12-1740 24170545 · DOI
  71. [87]Veninga V. Voest E.E. Tumor organoids: Opportunities and challenges to guide precision medicine Cancer Cell 2021 39 1190 1201 10.1016/j.ccell.2021.07.020 34416168 · DOI · Paper page
  72. [88]Li Y.F. Gao Y. Liang B.W. Cao X.Q. Sun Z.J. Yu J.H. Liu Z.D. Han Y. Patient-derived organoids of non-small cells lung cancer and their application for drug screening Neoplasma 2020 67 430 437 10.4149/neo_2020_190417N346 31973535 · DOI
  73. [89]Sandor G.O. Soos A.A. Lorincz P. Rojko L. Harko T. Bogyo L. Tolgyes T. Bursics A. Buzas E.I. Moldvay J. Wnt Activity and Cell Proliferation Are Coupled to Extracellular Vesicle Release in Multiple Organoid Models Front. Cell Dev. Biol. 2021 9 670825 10.3389/fcell.2021.670825 34249925 PMC8264557 · DOI
  74. [90]Dijkstra K.K. Monkhorst K. Schipper L.J. Hartemink K.J. Smit E.F. Kaing S. de Groot R. Wolkers M.C. Clevers H. Cuppen E. Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine Cell Rep. 2020 31 107588 10.1016/j.celrep.2020.107588 32375033 · DOI · Paper page
  75. [91]Taverna J.A. Hung C.N. DeArmond D.T. Chen M. Lin C.L. Osmulski P.A. Gaczynska M.E. Wang C.M. Lucio N.D. Chou C.W. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer Cancer Res. 2020 80 1551 1563 10.1158/0008-5472.CAN-19-3183 31992541 PMC7127959 · DOI
  76. [92]Li Z. Qian Y. Li W. Liu L. Yu L. Liu X. Wu G. Wang Y. Luo W. Fang F. Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening iScience 2020 23 101411 10.1016/j.isci.2020.101411 32771979 PMC7415928 · DOI
  77. [95]Choi S.Y. Cho Y.H. Kim D.S. Ji W. Choi C.M. Lee J.C. Rho J.K. Jeong G.S. Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids Int. J. Mol. Sci. 2021 22 1349 10.3390/ijms22031349 33572899 PMC7866263 · DOI
  78. [97]Endo H. Okami J. Okuyama H. Kumagai T. Uchida J. Kondo J. Takehara T. Nishizawa Y. Imamura F. Higashiyama M. Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation J. Thorac. Oncol. 2013 8 131 139 10.1097/JTO.0b013e3182779ccf 23328545 · DOI
  79. [98]Ooft S.N. Weeber F. Dijkstra K.K. McLean C.M. Kaing S. van Werkhoven E. Schipper L. Hoes L. Vis D.J. van de Haar J. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients Sci. Transl. Med. 2019 11 eaay2574 10.1126/scitranslmed.aay2574 31597751 · DOI · Paper page
  80. [99]Karthaus W.R. Iaquinta P.J. Drost J. Gracanin A. van Boxtel R. Wongvipat J. Dowling C.M. Gao D. Begthel H. Sachs N. Identification of multipotent luminal progenitor cells in human prostate organoid cultures Cell 2014 159 163 175 10.1016/j.cell.2014.08.017 25201529 PMC4772677 · DOI
  81. [100]Junttila M.R. de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response Nature 2013 501 346 354 10.1038/nature12626 24048067 · DOI · Paper page
  82. [101]Ruoslahti E. Specialization of tumour vasculature Nat. Rev. Cancer 2002 2 83 90 10.1038/nrc724 12635171 · DOI
  83. [102]Schaaf M.B. Garg A.D. Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy Cell Death Dis. 2018 9 115 10.1038/s41419-017-0061-0 29371595 PMC5833710 · DOI · Paper page
  84. [103]Li M.L. Aggeler J. Farson D.A. Hatier C. Hassell J. Bissell M.J. Influence of a reconstituted basement membrane and its components on casein gene expression and secretion in mouse mammary epithelial cells Proc. Natl. Acad. Sci. USA 1987 84 136 140 10.1073/pnas.84.1.136 3467345 PMC304157 · DOI
  85. [104]Shannon J.M. Mason R.J. Jennings S.D. Functional differentiation of alveolar type II epithelial cells in vitro: Effects of cell shape, cell-matrix interactions and cell-cell interactions Biochim. Biophys. Acta 1987 931 143 156 10.1016/0167-4889(87)90200-X 3663713 · DOI
  86. [105]Paradiso F. Serpelloni S. Francis L.W. Taraballi F. Mechanical Studies of the Third Dimension in Cancer: From 2D to 3D Model Int. J. Mol. Sci. 2021 22 10098 10.3390/ijms221810098 34576261 PMC8472581 · DOI
  87. [106]Henke E. Nandigama R. Ergun S. Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy Front. Mol. Biosci. 2019 6 160 10.3389/fmolb.2019.00160 32118030 PMC7025524 · DOI · Paper page
  88. [107]Nia H.T. Munn L.L. Jain R.K. Physical traits of cancer Science 2020 370 eaaz0868 10.1126/science.aaz0868 33122355 PMC8274378 · DOI
  89. [108]Sheridan C. Pancreatic cancer provides testbed for first mechanotherapeutics Nat. Biotechnol. 2019 37 829 831 10.1038/d41587-019-00019-2 31375797 · DOI
  90. [109]Hughes C.S. Postovit L.M. Lajoie G.A. Matrigel: A complex protein mixture required for optimal growth of cell culture Proteomics 2010 10 1886 1890 10.1002/pmic.200900758 20162561 · DOI · Paper page
  91. [110]Aisenbrey E.A. Murphy W.L. Synthetic alternatives to Matrigel Nat. Rev. Mater. 2020 5 539 551 10.1038/s41578-020-0199-8 32953138 PMC7500703 · DOI · Paper page
  92. [112]Lugano R. Ramachandran M. Dimberg A. Tumor angiogenesis: Causes, consequences, challenges and opportunities Cell Mol. Life Sci. 2020 77 1745 1770 10.1007/s00018-019-03351-7 31690961 PMC7190605 · DOI
  93. [113]Lee W.S. Yang H. Chon H.J. Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity Exp. Mol. Med. 2020 52 1475 1485 10.1038/s12276-020-00500-y 32913278 PMC8080646 · DOI
  94. [115]An F. Qu Y. Luo Y. Fang N. Liu Y. Gao Z. Zhao W. Lin B. A Laminated Microfluidic Device for Comprehensive Preclinical Testing in the Drug ADME Process Sci. Rep. 2016 6 25022 10.1038/srep25022 27122192 PMC4848557 · DOI
  95. [116]Glassman P.M. Myerson J.W. Ferguson L.T. Kiseleva R.Y. Shuvaev V.V. Brenner J.S. Muzykantov V.R. Targeting drug delivery in the vascular system: Focus on endothelium Adv. Drug Deliv. Rev. 2020 157 96 117 10.1016/j.addr.2020.06.013 32579890 PMC7306214 · DOI
  96. [117]Mitchell M.J. Jain R.K. Langer R. Engineering and physical sciences in oncology: Challenges and opportunities Nat. Rev. Cancer 2017 17 659 675 10.1038/nrc.2017.83 29026204 PMC5683724 · DOI · Paper page
  97. [120]Ramamonjisoa N. Ackerstaff E. Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging Front. Oncol. 2017 7 3 10.3389/fonc.2017.00003 28197395 PMC5281579 · DOI · Paper page
  98. [122]Asif P.J. Longobardi C. Hahne M. Medema J.P. The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis Cancers 2021 13 4720 10.3390/cancers13184720 34572947 PMC8472587 · DOI
  99. [123]Kretzschmar K. Clevers H. Organoids: Modeling Development and the Stem Cell Niche in a Dish Dev. Cell 2016 38 590 600 10.1016/j.devcel.2016.08.014 27676432 · DOI
  100. [124]Schilders K.A. Eenjes E. van Riet S. Poot A.A. Stamatialis D. Truckenmuller R. Hiemstra P.S. Rottier R.J. Regeneration of the lung: Lung stem cells and the development of lung mimicking devices Respir. Res. 2016 17 44 10.1186/s12931-016-0358-z 27107715 PMC4842297 · DOI
  101. [125]Hines E.A. Sun X. Tissue crosstalk in lung development J. Cell Biochem. 2014 115 1469 1477 10.1002/jcb.24811 24644090 PMC8631609 · DOI
  102. [126]Salahudeen A.A. Choi S.S. Rustagi A. Zhu J. Van Unen V. De La O S.M. Flynn R.A. Margalef-Català M. Santos A.J.M. Ju J. Progenitor identification and SARS-CoV-2 infection in human distal lung organoids Nature 2020 588 670 675 10.1038/s41586-020-3014-1 33238290 PMC8003326 · DOI · Paper page
  103. [127]Rabata A. Fedr R. Soucek K. Hampl A. Koledova Z. 3D Cell Culture Models Demonstrate a Role for FGF and WNT Signaling in Regulation of Lung Epithelial Cell Fate and Morphogenesis Front. Cell Dev. Biol. 2020 8 574 10.3389/fcell.2020.00574 32850782 PMC7396690 · DOI
  104. [128]Miller A.J. Dye B.R. Ferrer-Torres D. Hill D.R. Overeem A.W. Shea L.D. Spence J.R. Generation of lung organoids from human pluripotent stem cells in vitro Nat. Protoc. 2019 14 518 540 10.1038/s41596-018-0104-8 30664680 PMC6531049 · DOI
  105. [129]Nikolic M.Z. Caritg O. Jeng Q. Johnson J.A. Sun D. Howell K.J. Brady J.L. Laresgoiti U. Allen G. Butler R. Human embryonic lung epithelial tips are multipotent progenitors that can be expanded in vitro as long-term self-renewing organoids Elife 2017 6 e26575 10.7554/eLife.26575 28665271 PMC5555721 · DOI
  106. [130]Mou H. Vinarsky V. Tata P.R. Brazauskas K. Choi S.H. Crooke A.K. Zhang B. Solomon G.M. Turner B. Bihler H. Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells Cell Stem Cell 2016 19 217 231 10.1016/j.stem.2016.05.012 27320041 PMC4975684 · DOI
  107. [131]Chung M.I. Bujnis M. Barkauskas C.E. Kobayashi Y. Hogan B.L.M. Niche-mediated BMP/SMAD signaling regulates lung alveolar stem cell proliferation and differentiation Development 2018 145 dev163014 10.1242/dev.163014 29752282 PMC5992594 · DOI
  108. [132]Xu H. Lyu X. Yi M. Zhao W. Song Y. Wu K. Organoid technology and applications in cancer research J. Hematol. Oncol. 2018 11 116 10.1186/s13045-018-0662-9 30219074 PMC6139148 · DOI
  109. [133]Drost J. van Jaarsveld R.H. Ponsioen B. Zimberlin C. van Boxtel R. Buijs A. Sachs N. Overmeer R.M. Offerhaus G.J. Begthel H. Sequential cancer mutations in cultured human intestinal stem cells Nature 2015 521 43 47 10.1038/nature14415 25924068 · DOI · Paper page
  110. [134]Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer Nature 2012 487 330 337 10.1038/nature11252 22810696 PMC3401966 · DOI · Paper page
  111. [135]Fujii M. Shimokawa M. Date S. Takano A. Matano M. Nanki K. Ohta Y. Toshimitsu K. Nakazato Y. Kawasaki K. A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis Cell Stem Cell 2016 18 827 838 10.1016/j.stem.2016.04.003 27212702 · DOI · Paper page
  112. [136]Akiri G. Cherian M.M. Vijayakumar S. Liu G. Bafico A. Aaronson S.A. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma Oncogene 2009 28 2163 2172 10.1038/onc.2009.82 19377513 PMC4451819 · DOI
  113. [137]Uematsu K. He B. You L. Xu Z. McCormick F. Jablons D.M. Activation of the Wnt pathway in non small cell lung cancer: Evidence of dishevelled overexpression Oncogene 2003 22 7218 7221 10.1038/sj.onc.1206817 14562050 · DOI
  114. [138]Tammela T. Sanchez-Rivera F.J. Cetinbas N.M. Wu K. Joshi N.S. Helenius K. Park Y. Azimi R. Kerper N.R. Wesselhoeft R.A. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma Nature 2017 545 355 359 10.1038/nature22334 28489818 PMC5903678 · DOI
  115. [139]Yoder D.G. Moody T.W. High affinity binding of cholecystokinin to small cell lung cancer cells Peptides 1987 8 103 107 10.1016/0196-9781(87)90171-9 3033616 · DOI
  116. [140]Staley J. Jensen R.T. Moody T.W. CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells Peptides 1990 11 1033 1036 10.1016/0196-9781(90)90029-5 2178246 · DOI
  117. [141]Moody T.W. Jensen R.T. CI-988 inhibits growth of small cell lung cancer cells J. Pharmacol. Exp. Ther. 2001 299 1154 1160 11714907
  118. [142]Staley J. Fiskum G. Moody T.W. Cholecystokinin elevates cytosolic calcium in small cell lung cancer cells Biochem. Biophys. Res. Commun. 1989 163 605 610 10.1016/0006-291X(89)92180-3 2550000 · DOI
  119. [143]Lemmon M.A. Schlessinger J. Cell signaling by receptor tyrosine kinases Cell 2010 141 1117 1134 10.1016/j.cell.2010.06.011 20602996 PMC2914105 · DOI · Paper page
  120. [144]Yue D. Li H. Che J. Zhang Y. Tseng H.H. Jin J.Q. Luh T.M. Giroux-Leprieur E. Mo M. Zheng Q. Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas J. Exp. Clin. Cancer Res. 2014 33 34 10.1186/1756-9966-33-34 24758269 PMC4029998 · DOI
  121. [145]Szczepny A. Rogers S. Jayasekara W.S.N. Park K. McCloy R.A. Cochrane C.R. Ganju V. Cooper W.A. Sage J. Peacock C.D. The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer Oncogene 2017 36 5544 5550 10.1038/onc.2017.173 28581526 PMC5623150 · DOI
  122. [146]Watkins D.N. Berman D.M. Burkholder S.G. Wang B. Beachy P.A. Baylin S.B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer Nature 2003 422 313 317 10.1038/nature01493 12629553 · DOI
  123. [147]Park K.S. Martelotto L.G. Peifer M. Sos M.L. Karnezis A.N. Mahjoub M.R. Bernard K. Conklin J.F. Szczepny A. Yuan J. A crucial requirement for Hedgehog signaling in small cell lung cancer Nat. Med. 2011 17 1504 1508 10.1038/nm.2473 21983857 PMC3380617 · DOI
  124. [148]Giroux Leprieur E. Tolani B. Li H. Leguay F. Hoang N.T. Acevedo L.A. Jin J.Q. Tseng H.H. Yue D. Kim I.J. Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer Oncotarget 2017 8 103744 103757 10.18632/oncotarget.21781 29262597 PMC5732763 · DOI
  125. [149]Fan Y. Wang Y. Wang K. Prostaglandin E2 stimulates normal bronchial epithelial cell growth through induction of c-Jun and PDK1, a kinase implicated in oncogenesis Respir. Res. 2015 16 149 10.1186/s12931-015-0309-0 26684827 PMC4699375 · DOI
  126. [150]Bai X. Yang Q. Shu W. Wang J. Zhang L. Ma J. Xia S. Zhang M. Cheng S. Wang Y. Prostaglandin E2 upregulates beta1 integrin expression via the E prostanoid 1 receptor/nuclear factor kappa-light-chain-enhancer of activated B cells pathway in non-small-cell lung cancer cells Mol. Med. Rep. 2014 9 1729 1736 10.3892/mmr.2014.2000 24584670 · DOI
  127. [151]Wang T. Jing B. Sun B. Liao Y. Song H. Xu D. Guo W. Li K. Hu M. Liu S. Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE2 signaling Am. J. Cancer Res. 2019 9 1145 1160 31285948 PMC6610053
  128. [152]Barovsky K. Pedone C. Brooker G. Distinct mechanisms of forskolin-stimulated cyclic AMP accumulation and forskolin-potentiated hormone responses in C6-2B cells Mol. Pharmacol. 1984 25 256 260 6321948
  129. [153]Jahchan N.S. Dudley J.T. Mazur P.K. Flores N. Yang D. Palmerton A. Zmoos A.F. Vaka D. Tran K.Q. Zhou M. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors Cancer Discov. 2013 3 1364 1377 10.1158/2159-8290.CD-13-0183 24078773 PMC3864571 · DOI
  130. [154]Xia Y. Zhan C. Feng M. Leblanc M. Ke E. Yeddula N. Verma I.M. Targeting CREB Pathway Suppresses Small Cell Lung Cancer Mol. Cancer Res. 2018 16 825 832 10.1158/1541-7786.MCR-17-0576 29523765 PMC5932136 · DOI
  131. [155]Seo H.-S. Liu D.D. Bekele B.N. Kim M.-K. Pisters K.M.W. Lippman S.M. Wistuba I.I. Koo J.S. Cyclic AMP response element-binding protein overexpression: A feature associated with negative prognosis in never smokers with non-small cell lung cancer Cancer Res. 2008 68 6065 6073 10.1158/0008-5472.CAN-07-5376 18676828 PMC3058903 · DOI
  132. [156]Yang J. Wang X. Gao Y. Fang C. Ye F. Huang B. Li L. Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma Onco Targets Ther. 2020 13 8197 8208 10.2147/OTT.S263977 32904445 PMC7455753 · DOI
  133. [157]Khuri F.R. Wu H. Lee J.J. Kemp B.L. Lotan R. Lippman S.M. Feng L. Hong W.K. Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer Clin. Cancer Res. 2001 7 861 867 11309334
  134. [158]Petkova D.K. Clelland C. Ronan J. Pang L. Coulson J.M. Lewis S. Knox A.J. Overexpression of cyclooxygenase-2 in non-small cell lung cancer Respir. Med. 2004 98 164 172 10.1016/j.rmed.2003.09.006 14971881 · DOI
  135. [159]Wu Y.C. Su L.J. Wang H.W. Jeff Lin C.F. Hsu W.H. Chou T.Y. Huang C.Y. Lu C.L. Hsueh C.T. Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer J. Thorac. Oncol. 2010 5 1167 1174 10.1097/JTO.0b013e3181e2f4f5 20592629 · DOI
  136. [160]Capparelli C. Rosenbaum S. Berger A.C. Aplin A.E. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma J. Biol. Chem. 2015 290 24267 24277 10.1074/jbc.M115.657270 26269601 PMC4591813 · DOI
  137. [161]Zhou B.B. Peyton M. He B. Liu C. Girard L. Caudler E. Lo Y. Baribaud F. Mikami I. Reguart N. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer Cancer Cell 2006 10 39 50 10.1016/j.ccr.2006.05.024 16843264 PMC4451119 · DOI
  138. [162]Mota J.M. Collier K.A. Barros Costa R.L. Taxter T. Kalyan A. Leite C.A. Chae Y.K. Giles F.J. Carneiro B.A. A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer Oncotarget 2017 8 89284 89306 10.18632/oncotarget.18467 29179520 PMC5687690 · DOI
  139. [163]Hua H. Kong Q. Yin J. Zhang J. Jiang Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: A challenge for cancer therapy J. Hematol. Oncol. 2020 13 64 10.1186/s13045-020-00904-3 32493414 PMC7268628 · DOI
  140. [164]Boccaccio C. Comoglio P.M. Invasive growth: A MET-driven genetic programme for cancer and stem cells Nat. Rev. Cancer 2006 6 637 645 10.1038/nrc1912 16862193 · DOI
  141. [165]Corso S. Comoglio P.M. Giordano S. Cancer therapy: Can the challenge be MET? Trends Mol. Med. 2005 11 284 292 10.1016/j.molmed.2005.04.005 15949770 · DOI
  142. [166]Zhang M. Li X. Zhang X. Yang Y. Feng Z. Liu X. Association of serum hemoglobin A1c, C-peptide and insulin-like growth factor-1 levels with the occurrence and development of lung cancer Mol. Clin. Oncol. 2014 2 506 508 10.3892/mco.2014.289 24940485 PMC4051575 · DOI
  143. [167]Ozasa H. Oguri T. Maeno K. Takakuwa O. Kunii E. Yagi Y. Uemura T. Kasai D. Miyazaki M. Niimi A. Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells Cancer Sci. 2014 105 1032 1039 10.1111/cas.12447 24827412 PMC4317853 · DOI
  144. [168]Christensen J.G. Burrows J. Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention Cancer Lett. 2005 225 1 26 10.1016/j.canlet.2004.09.044 15922853 · DOI
  145. [169]Hoda M.A. Rozsas A. Lang E. Klikovits T. Lohinai Z. Torok S. Berta J. Bendek M. Berger W. Hegedus B. High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma Oncotarget 2016 7 13388 13399 10.18632/oncotarget.7796 26950277 PMC4924649 · DOI
  146. [170]Seder C.W. Hartojo W. Lin L. Silvers A.L. Wang Z. Thomas D.G. Giordano T.J. Chen G. Chang A.C. Orringer M.B. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma Neoplasia 2009 11 388 396 10.1593/neo.81582 19308293 PMC2657883 · DOI
  147. [171]Wamsley J.J. Kumar M. Allison D.F. Clift S.H. Holzknecht C.M. Szymura S.J. Hoang S.A. Xu X. Moskaluk C.A. Jones D.R. Activin upregulation by NF-kappaB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer Cancer Res. 2015 75 426 435 10.1158/0008-5472.CAN-13-2702 25432175 PMC4297542 · DOI
  148. [172]Rodrigues C.F.D. Serrano E. Patricio M.I. Val M.M. Albuquerque P. Fonseca J. Gomes C.M.F. Abrunhosa A.J. Paiva A. Carvalho L. Stroma-derived IL-6, G-CSF and Activin-A mediated dedifferentiation of lung carcinoma cells into cancer stem cells Sci. Rep. 2018 8 11573 10.1038/s41598-018-29947-w 30069023 PMC6070555 · DOI
  149. [173]Suwinski P. Ong C. Ling M.H.T. Poh Y.M. Khan A.M. Ong H.S. Advancing Personalized Medicine Through the Application of Whole Exome Sequencing and Big Data Analytics Front. Genet. 2019 10 49 10.3389/fgene.2019.00049 30809243 PMC6379253 · DOI
  150. [174]Kumar M.P. Du J. Lagoudas G. Jiao Y. Sawyer A. Drummond D.C. Lauffenburger D.A. Raue A. Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics Cell Rep. 2018 25 1458 1468.e4 10.1016/j.celrep.2018.10.047 30404002 PMC7009724 · DOI
  151. [175]Nii T. Makino K. Tabata Y. Three-Dimensional Culture System of Cancer Cells Combined with Biomaterials for Drug Screening Cancers 2020 12 2754 10.3390/cancers12102754 PMC7601447 32987868 · DOI
  152. [176]Vu T.T. Lim C. Lim M. Characterization of leukemic cell behaviors in a soft marrow mimetic alginate hydrogel J. Biomed. Mater. Res. B Appl. Biomater. 2012 100 1980 1988 10.1002/jbm.b.32765 22888018 · DOI
  153. [177]Liu C. Liu Y. Xu X.X. Wu H. Xie H.G. Chen L. Lu T. Yang L. Guo X. Sun G.W. Potential effect of matrix stiffness on the enrichment of tumor initiating cells under three-dimensional culture conditions Exp. Cell Res. 2015 330 123 134 10.1016/j.yexcr.2014.07.036 25108138 · DOI
  154. [178]Liu C. Liu Y. Xu X.X. Guo X. Sun G.W. Ma X.J. Mesenchymal stem cells enhance the metastasis of 3D-cultured hepatocellular carcinoma cells BMC Cancer 2016 16 566 10.1186/s12885-016-2595-4 27475525 PMC4967520 · DOI
  155. [179]Liu C. Liu Y. Xie H.G. Zhao S. Xu X.X. Fan L.X. Guo X. Lu T. Sun G.W. Ma X.J. Role of three-dimensional matrix stiffness in regulating the chemoresistance of hepatocellular carcinoma cells Biotechnol. Appl. Biochem. 2015 62 556 562 10.1002/bab.1302 25274163 · DOI
  156. [180]Cavo M. Caria M. Pulsoni I. Beltrame F. Fato M. Scaglione S. A new cell-laden 3D Alginate-Matrigel hydrogel resembles human breast cancer cell malignant morphology, spread and invasion capability observed “in vivo” Sci. Rep. 2018 8 5333 10.1038/s41598-018-23250-4 29593247 PMC5871779 · DOI
  157. [181]Estrada M.F. Rebelo S.P. Davies E.J. Pinto M.T. Pereira H. Santo V.E. Smalley M.J. Barry S.T. Gualda E.J. Alves P.M. Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression Biomaterials 2016 78 50 61 10.1016/j.biomaterials.2015.11.030 26650685 · DOI
  158. [182]Liu C. Lewin Mejia D. Chiang B. Luker K.E. Luker G.D. Hybrid collagen alginate hydrogel as a platform for 3D tumor spheroid invasion Acta Biomater. 2018 75 213 225 10.1016/j.actbio.2018.06.003 29879553 PMC6119473 · DOI
  159. [183]DelNero P. Lane M. Verbridge S.S. Kwee B. Kermani P. Hempstead B. Stroock A. Fischbach C. 3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways Biomaterials 2015 55 110 118 10.1016/j.biomaterials.2015.03.035 25934456 PMC4417672 · DOI
  160. [184]Nii T. Makino K. Tabata Y. A Cancer Invasion Model Combined with Cancer-Associated Fibroblasts Aggregates Incorporating Gelatin Hydrogel Microspheres Containing a p53 Inhibitor Tissue Eng. Part C Methods 2019 25 711 720 10.1089/ten.tec.2019.0189 31621504 · DOI
  161. [185]Brancato V. Comunanza V. Imparato G. Cora D. Urciuolo F. Noghero A. Bussolino F. Netti P.A. Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer Acta Biomater. 2017 49 152 166 10.1016/j.actbio.2016.11.072 27916739 · DOI
  162. [186]Nii T. Makino K. Tabata Y. A cancer invasion model of cancer-associated fibroblasts aggregates combined with TGF-beta1 release system Regen. Ther. 2020 14 196 204 10.1016/j.reth.2020.02.003 32154334 PMC7058408 · DOI
  163. [187]Brancato V. Gioiella F. Imparato G. Guarnieri D. Urciuolo F. Netti P.A. 3D breast cancer microtissue reveals the role of tumor microenvironment on the transport and efficacy of free-doxorubicin in vitro Acta Biomater. 2018 75 200 212 10.1016/j.actbio.2018.05.055 29864516 · DOI
  164. [188]Mazio C. Casale C. Imparato G. Urciuolo F. Netti P.A. Recapitulating spatiotemporal tumor heterogeneity in vitro through engineered breast cancer microtissues Acta Biomater. 2018 73 236 249 10.1016/j.actbio.2018.04.028 29679778 · DOI
  165. [189]Pradhan S. Clary J.M. Seliktar D. Lipke E.A. A three-dimensional spheroidal cancer model based on PEG-fibrinogen hydrogel microspheres Biomaterials 2017 115 141 154 10.1016/j.biomaterials.2016.10.052 27889665 · DOI
  166. [190]Pradhan S. Hassani I. Seeto W.J. Lipke E.A. PEG-fibrinogen hydrogels for three-dimensional breast cancer cell culture J. Biomed. Mater. Res. A 2017 105 236 252 10.1002/jbm.a.35899 27615742 · DOI
  167. [191]Yang X. Sarvestani S.K. Moeinzadeh S. He X. Jabbari E. Three-dimensional-engineered matrix to study cancer stem cells and tumorsphere formation: Effect of matrix modulus Tissue Eng. Part A 2013 19 669 684 10.1089/ten.tea.2012.0333 23013450 PMC3566656 · DOI
  168. [192]Engel B.J. Constantinou P.E. Sablatura L.K. Doty N.J. Carson D.D. Farach-Carson M.C. Harrington D.A. Zarembinski T.I. Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures Adv. Healthc. Mater. 2015 4 1664 1674 10.1002/adhm.201500258 26059746 PMC4545642 · DOI
  169. [193]Dhiman H.K. Ray A.R. Panda A.K. Characterization and evaluation of chitosan matrix for in vitro growth of MCF-7 breast cancer cell lines Biomaterials 2004 25 5147 5154 10.1016/j.biomaterials.2003.12.025 15109838 · DOI
  170. [194]Broguiere N. Isenmann L. Hirt C. Ringel T. Placzek S. Cavalli E. Ringnalda F. Villiger L. Zullig R. Lehmann R. Growth of Epithelial Organoids in a Defined Hydrogel Adv. Mater. 2018 30 e1801621 10.1002/adma.201801621 30203567 · DOI · Paper page
  171. [195]Xiao W. Zhang R. Sohrabi A. Ehsanipour A. Sun S. Liang J. Walthers C.M. Ta L. Nathanson D.A. Seidlits S.K. Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma Cancer Res. 2018 78 1358 1370 10.1158/0008-5472.CAN-17-2429 29282221 PMC5935550 · DOI
  172. [196]Hernandez-Gordillo V. Kassis T. Lampejo A. Choi G. Gamboa M.E. Gnecco J.S. Brown A. Breault D.T. Carrier R. Griffith L.G. Fully synthetic matrices for in vitro culture of primary human intestinal enteroids and endometrial organoids Biomaterials 2020 254 120125 10.1016/j.biomaterials.2020.120125 32502894 PMC8005336 · DOI
  173. [197]Wimmer R.A. Leopoldi A. Aichinger M. Kerjaschki D. Penninger J.M. Generation of blood vessel organoids from human pluripotent stem cells Nat. Protoc. 2019 14 3082 3100 10.1038/s41596-019-0213-z 31554955 · DOI · Paper page
  174. [198]Ahn Y. An J.H. Yang H.J. Lee D.G. Kim J. Koh H. Park Y.H. Song B.S. Sim B.W. Lee H.J. Human Blood Vessel Organoids Penetrate Human Cerebral Organoids and Form a Vessel-Like System Cells 2021 10 2036 10.3390/cells10082036 34440805 PMC8393185 · DOI
  175. [199]Ham O. Jin Y.B. Kim J. Lee M.O. Blood vessel formation in cerebral organoids formed from human embryonic stem cells Biochem. Biophys. Res. Commun. 2020 521 84 90 10.1016/j.bbrc.2019.10.079 31629471 · DOI
  176. [200]Lai B.F.L. Lu R.X.Z. Davenport Huyer L. Kakinoki S. Yazbeck J. Wang E.Y. Wu Q. Zhang B. Radisic M. A well plate-based multiplexed platform for incorporation of organoids into an organ-on-a-chip system with a perfusable vasculature Nat. Protoc. 2021 16 2158 2189 10.1038/s41596-020-00490-1 33790475 · DOI
  177. [201]Haase K. Offeddu G.S. Gillrie M.R. Kamm R.D. Endothelial Regulation of Drug Transport in a 3D Vascularized Tumor Model Adv. Funct. Mater. 2020 30 2002444 10.1002/adfm.202002444 33692661 PMC7939067 · DOI
  178. [204]Odde D.J. Renn M.J. Laser-guided direct writing for applications in biotechnology Trends Biotechnol. 1999 17 385 389 10.1016/S0167-7799(99)01355-4 10481169 · DOI
  179. [205]Liu Y. Zhang Y. Mei T. Cao H. Hu Y. Jia W. Wang J. Zhang Z. Wang Z. Le W. hESCs-Derived Early Vascular Cell Spheroids for Cardiac Tissue Vascular Engineering and Myocardial Infarction Treatment Adv. Sci. 2022 9 2104299 10.1002/advs.202104299 35092352 PMC8948571 · DOI
  180. [206]De Moor L. Smet J. Plovyt M. Bekaert B. Vercruysse C. Asadian M. De Geyter N. Van Vlierberghe S. Dubruel P. Declercq H. Engineering microvasculature by 3D bioprinting of prevascularized spheroids in photo-crosslinkable gelatin Biofabrication 2021 13 045021 10.1088/1758-5090/ac24de 34496350 · DOI
  181. [207]Zhu W. Yu C. Sun B. Chen S. Bioprinting of Complex Vascularized Tissues Methods Mol. Biol. 2021 2147 163 173 10.1007/978-1-0716-0611-7_14 32840819 · DOI
  182. [208]Mollica P.A. Booth-Creech E.N. Reid J.A. Zamponi M. Sullivan S.M. Palmer X.L. Sachs P.C. Bruno R.D. 3D bioprinted mammary organoids and tumoroids in human mammary derived ECM hydrogels Acta Biomater. 2019 95 201 213 10.1016/j.actbio.2019.06.017 31233891 PMC6710129 · DOI · Paper page
  183. [209]Skylar-Scott M.A. Uzel S.G.M. Nam L.L. Ahrens J.H. Truby R.L. Damaraju S. Lewis J.A. Biomanufacturing of organ-specific tissues with high cellular density and embedded vascular channels Sci. Adv. 2019 5 eaaw2459 10.1126/sciadv.aaw2459 31523707 PMC6731072 · DOI
  184. [210]Luo Z. Zhou X. Mandal K. He N. Wennerberg W. Qu M. Jiang X. Sun W. Khademhosseini A. Reconstructing the tumor architecture into organoids Adv. Drug Deliv. Rev. 2021 176 113839 10.1016/j.addr.2021.113839 34153370 PMC8560135 · DOI
  185. [212]Cattaneo C.M. Dijkstra K.K. Fanchi L.F. Kelderman S. Kaing S. van Rooij N. van den Brink S. Schumacher T.N. Voest E.E. Tumor organoid-T-cell coculture systems Nat. Protoc. 2020 15 15 39 10.1038/s41596-019-0232-9 31853056 PMC7610702 · DOI · Paper page
  186. [213]Scognamiglio G. De Chiara A. Parafioriti A. Armiraglio E. Fazioli F. Gallo M. Aversa L. Camerlingo R. Cacciatore F. Colella G. Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors Br. J. Cancer 2019 121 979 982 10.1038/s41416-019-0616-1 31666667 PMC6889147 · DOI
  187. [214]Holokai L. Chakrabarti J. Lundy J. Croagh D. Adhikary P. Richards S.S. Woodson C. Steele N. Kuester R. Scott A. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma Cancers 2020 12 3816 10.3390/cancers12123816 33348809 PMC7766822 · DOI
  188. [216]Chalabi M. Fanchi L.F. Dijkstra K.K. Van den Berg J.G. Aalbers A.G. Sikorska K. Lopez-Yurda M. Grootscholten C. Beets G.L. Snaebjornsson P. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers Nat. Med. 2020 26 566 576 10.1038/s41591-020-0805-8 32251400 · DOI · Paper page
  189. [217]Zhang Z. Shiratsuchi H. Lin J. Chen G. Reddy R.M. Azizi E. Fouladdel S. Chang A.C. Lin L. Jiang H. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model Oncotarget 2014 5 12383 12397 10.18632/oncotarget.2592 25474037 PMC4323004 · DOI · Paper page
  190. [218]Nakamura H. Sugano M. Miyashita T. Hashimoto H. Ochiai A. Suzuki K. Tsuboi M. Ishii G. Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells Lung Cancer 2019 134 100 107 10.1016/j.lungcan.2019.04.007 31319967 · DOI
  191. [219]Liu J. Li P. Wang L. Li M. Ge Z. Noordam L. Lieshout R. Verstegen M.M.A. Ma B. Su J. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance Cell. Mol. Gastroenterol. Hepatol. 2021 11 407 431 10.1016/j.jcmgh.2020.09.003 32932015 PMC7788239 · DOI
  192. [220]Ebbing E.A. van der Zalm A.P. Steins A. Creemers A. Hermsen S. Rentenaar R. Klein M. Waasdorp C. Hooijer G.K.J. Meijer S.L. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma Proc. Natl. Acad. Sci. USA 2019 116 2237 2242 10.1073/pnas.1820459116 30670657 PMC6369811 · DOI
  193. [221]Joseph X. Akhil V. Arathi A. Mohanan P.V. Comprehensive Development in Organ-On-A-Chip Technology J. Pharm. Sci. 2022 111 18 31 10.1016/j.xphs.2021.07.014 34324944 · DOI
  194. [223]Jain A. van der Meer A.D. Papa A.L. Barrile R. Lai A. Schlechter B.L. Otieno M.A. Louden C.S. Hamilton G.A. Michelson A.D. Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium Biomed. Microdevices 2016 18 73 10.1007/s10544-016-0095-6 27464497 PMC4963439 · DOI · Paper page
  195. [224]Khoo B.L. Grenci G. Lim Y.B. Lee S.C. Han J. Lim C.T. Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device Nat. Protoc. 2018 13 34 58 10.1038/nprot.2017.125 29215634 · DOI · Paper page
  196. [225]Herland A. Maoz B.M. Das D. Somayaji M.R. Prantil-Baun R. Novak R. Cronce M. Huffstater T. Jeanty S.S.F. Ingram M. Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips Nat. Biomed. Eng. 2020 4 421 436 10.1038/s41551-019-0498-9 31988459 PMC8011576 · DOI
  197. [226]Liu D. Jiao S. Wei J. Zhang X. Pei Y. Pei Z. Li J. Du Y. Investigation of absorption, metabolism and toxicity of ginsenosides compound K based on human organ chips Int. J. Pharm. 2020 587 119669 10.1016/j.ijpharm.2020.119669 32702454 · DOI
  198. [228]Schuster B. Junkin M. Kashaf S.S. Romero-Calvo I. Kirby K. Matthews J. Weber C.R. Rzhetsky A. White K.P. Tay S. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids Nat. Commun. 2020 11 5271 10.1038/s41467-020-19058-4 33077832 PMC7573629 · DOI · Paper page
  199. [229]Jung D.J. Shin T.H. Kim M. Sung C.O. Jang S.J. Jeong G.S. A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity Lab Chip 2019 19 2854 2865 10.1039/C9LC00496C 31367720 · DOI
  200. [230]Ostman A. The tumor microenvironment controls drug sensitivity Nat. Med. 2012 18 1332 1334 10.1038/nm.2938 22961158 · DOI

200 of 206 shown

Cited by

Sorted by citations

Authors
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J.
Affiliations
  • Department of Research and Development, OncoClew Co., Ltd., Seoul 04778, Korea
  • Asan Medical Center (KR)
Corresponding author
Jang, Se Jin
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2022-04-25
Volume
14
Issue
9
Pages
2144
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers14092144
PMC
PMC9105149
OpenAlex
W4224866871
Cited by
27
References
33
Citations by year
2026: 7 · 2025: 8 · 2024: 6 · 2023: 6
FWCI
0.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Research Foundation of Korea (NRF-2019M3E5D3071926)
  • Korea Health Industry Development Institute (HR21C0198)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords
patient-derived cancer organoids, anticancer drug screening, precision medicine, tumor heterogeneity, patient stratification, anticancer drug development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review